AURA
Aura Biosciences, Inc.
-0.09 (-1.34%)6.64USD265K成交股數689M市值–本益比(近四季)100.4股價營收比+37.5%營收年增(近四季)2026-11-12下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 2.3M+45% | 1.2M-42% | 1.8M-20% | 1.7M-32% | 1.6M-41% | 2.0M+3% | 2.3M+12% | 2.5M+23% | 2.7M | 2.0M | 2.0M | 2.0M |
| 營業成本 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 研發費用 | 30.7M | 28.0M | 22.2M | 22.9M | 23.3M | 22.3M | 17.0M | 16.9M | 17.1M | 15.4M | 15.1M | 14.4M |
| 銷售管理費用 | 17.3M | 6.9M | 5.7M | 5.7M | 5.7M | 5.5M | 6.2M | 5.9M | 5.3M | 5.1M | 5.2M | 5.0M |
| 營業利益 | −48.1M+66% | −34.9M+25% | −27.9M+20% | −28.6M+26% | −29.0M+30% | −27.8M+36% | −23.2M+15% | −22.8M+17% | −22.3M | −20.5M | −20.3M | −19.4M |
| 營業利益率 | -2,083.6% | -2,929.9% | -1,537.5% | -1,705.2% | -1,821.5% | -1,366.5% | -1,028.9% | -928.7% | -831.0% | -1,034.2% | -1,009.3% | -976.6% |
| 稅後淨利 | −45.6M+66% | −33.7M+30% | −26.1M+24% | −27.0M+33% | −27.5M+39% | −25.8M+40% | −21.0M+15% | −20.3M+16% | −19.7M | −18.5M | −18.3M | −17.5M |
| 淨利率 | -1,978.2% | -2,830.7% | -1,439.7% | -1,610.2% | -1,724.2% | -1,269.5% | -931.9% | -829.7% | -733.9% | -934.5% | -910.9% | -877.2% |
| 稀釋 EPS | -0.48-13% | -0.50-4% | -0.40-5% | -0.47+15% | -0.55+38% | -0.52+8% | -0.42-13% | -0.41-11% | -0.40 | -0.48 | -0.48 | -0.46 |
| 稀釋股數 | 94.9M | 67.4M | 65.9M | 58.0M | 50.1M | 49.7M | 49.7M | 49.5M | 49.5M | 38.2M | 37.9M | 37.8M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 67.8M | 84.8M | 47.6M | 107M | 38.2M | 31.7M | 25.4M | 30.1M | 26.3M | 55.6M | 47.7M | 38.5M |
| 應收帳款 | – | – | – | – | – | – | – | – | – | – | – | – |
| 存貨 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總資產 | 348M | 138M | 190M | 204M | 155M | 183M | 205M | 218M | 235M | 180M | 193M | 206M |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 32.9M | 30.4M | 33.4M | 29.8M | 27.4M | 30.5M | 30.7M | 26.8M | 26.2M | 28.0M | 26.3M | 25.8M |
| 股東權益 | 315M | 107M | 157M | 175M | 128M | 152M | 175M | 191M | 209M | 152M | 166M | 180M |
| 負債比 | 9.4% | 22.1% | 17.6% | 14.6% | 17.7% | 16.7% | 14.9% | 12.3% | 11.2% | 15.6% | 13.6% | 12.5% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −29.9M | – | – | −23.4M-4% | – | – | – | −24.5M | – | – | −16.4M |
| 資本支出 | – | 102K | – | – | 187K | – | – | – | 88K | – | – | 109K |
| 自由現金流 | – | −30.0M | – | – | −23.5M-4% | – | – | – | −24.5M | – | – | −16.5M |
| 折舊攤銷 | – | – | – | – | – | – | – | – | – | – | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | -2,520.6% | – | – | -1,476.9% | – | – | – | -914.0% | – | – | -829.8% |
營收拆解
這家公司的 XBRL 沒有標分部、產品或地區營收。多半是單一業務,或只在 10-K 文字裡揭露。
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 6.6M | -29.7% | −106M | -1,601.4% | -1.76 | −85.2M |
| FY2024 | 9.4M | +9.8% | −86.9M | -921.8% | -1.75 | −81.1M |
| FY2023 | 8.6M | +360.7% | −76.4M | -889.7% | -1.93 | −64.6M |
| FY2022 | 1.9M | +14238.5% | −58.8M | -3,152.5% | -1.96 | −55.7M |
| FY2021 | 13K | -533.3% | −35.3M | -271,161.5% | -8.95 | −34.5M |
| FY2020 | −3K | – | −22.2M | 740,200.0% | -82.06 | −25.1M |